Retraction Note to: Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study

Michael Strupp¹ · Ludwig Kraus¹ · Franz Schautzer² · Dan Rujescu^{1,3}

Published online: 18 March 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Retraction Note to:
Journal of Neurology (2018) 265 (Suppl 1):S80–S85
<https://doi.org/10.1007/s00415-018-8809-8>

The authors have retracted this article [1] because it erroneously gives the impression that the results presented were based on a clinical trial, when in fact the patients treated in this observational study underwent so-called “individuelle Heilversuche” (individual patient treatment). “Individuelle Heilversuche” is a type of medical treatment that deviates from the established medical standard. The healing attempt is aimed primarily at curing a specific patient, rather than conducting experimental research. Therefore,

these individual healing attempts cannot be referred to as a clinical study. All authors agree with this retraction.

Reference

1. Strupp M, Kraus L, Schautzer F, Rujescu D (2018) Menière's disease: combined pharmacotherapy with betahistine and the MAO-B inhibitor selegiline—an observational study. *J Neurol* 265:s80–s85. <https://doi.org/10.1007/s00415-018-8809-8>

The original article can be found online at <https://doi.org/10.1007/s00415-018-8809-8>.

✉ Michael Strupp
Michael.Strupp@med.uni-muenchen.de

- ¹ Department of Neurology and German Center for Vertigo and Balance Disorders (DSGZ), Ludwig Maximilians University, Munich, Campus Grosshadern, Marchioninistr. 15, 81377 Munich, Germany
- ² Department of Neurology, Landeskrankenhaus Villach, Villach, Austria
- ³ Department of Psychiatry, University Hospital Halle, Halle, Germany